Adaptation of a Public–Private Partnership Model for the Implementation of Minipool Nucleic Acid Testing for Screening Routine Blood Donations and Assay Evaluation

Smita Mahapatra¹ Pankaj Parida¹ Chitta Ranjan Prasad² Sabita Palai⁴ Debashis Mishra³
Susmita Behera⁴ Rabindra Kumar Mishra⁴ Binayak Prasad Prusty⁵ Kalyan Sarkar⁶

¹Department of Transfusion Medicine, Sri-Rama Chandra Bhanja Medical College & Hospital, Cuttack, Odisha, India
²Department of Transfusion Medicine, Veer Surendra Sai Institute of Medical Sciences and Research, Burla, Odisha, India
³Blood Bank, Capital Hospital, Bhubaneswar, Odisha, India
⁴Transfusion Medicine, Maharaja Krishna Chandra Gajapati Medical College Hospital, Berhampur, Odisha, India
⁵Central Red Cross Blood Bank, Cuttack, Odisha, India
⁶BMC Hospital, Bhubaneswar, Odisha, India

Address for correspondence Smita Mahapatra, MD, Department of Transfusion Medicine, Sri-Rama Chandra Bhanja Medical College & Hospital, Cuttack, 753001, Odisha, India (e-mail: dr.smitamahapatra@gmail.com).

J Lab Physicians 2022;14:317–323.

Abstract

Background Nucleic acid amplification testing (NAT) for the screening of blood donations is known to improve blood safety. The decision to initiate NAT requires careful deliberation of infrastructure, skilled manpower, and financial resources. This report outlines the initiative of the Government of Odisha to implement NAT screening in government blood banks in the state of Odisha, India, through public–private partnership (PPP) and evaluates the incremental yield of minipool NAT screening over serology testing of blood donations.

Methods Blood donations collected between June 2016 and September 2018 were initially screened for HBV (HBsAg), HCV (anti-HCV), and HIV (anti-HIV-1 and HIV-2) by ELISA, and syphilis and malaria. Sero-nonreactive donations were further screened in pools of six by Roche cobas TaqScreen MPX test version 2.0 (MPX2) NAT.

Results On screening 3,39,472 blood donations, 1.34% seroreactive donations were detected. In all, 847 NAT-reactive donations (0.26%): 693 HBV, 58 HCV, and 96 HIV were detected. The NAT yields were 1:386 overall, 1:472 for HBV, 1:5642 for HCV, and 1:3409 for HIV.

Conclusion NAT testing using the highly sensitive MPX2 assay leads to incremental detection of TTIs over serology. Implementation of NAT along with serological testing in blood centers all over India will be an important step towards providing safe blood. Our study not only highlights the benefits of minipool NAT testing but also presents a scalable PPP model that can serve as a template for application across other states.

Keywords ► nucleic acid amplification technology ► minipool ► transfusion-transmitted infection ► blood donation ► public–private partnership model ► NAT yield

DOI https://doi.org/10.1055/s-0042-1748825. ISSN 0974-2727.

© 2022. The Indian Association of Laboratory Physicians. All rights reserved.
This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd., A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
Introduction

India is able to collect only 9 million units against an annual demand of 12 million units, that is, 1.2 crore units for transfusion per year and a high prevalence of potential transfusion-transmitted infections (TTIs) across different states. The National AIDS Control Organization (NACO), and National Blood Transfusion Council (NBTC) of India’s assessment shows seropositivity of TTI among blood donors to be the highest for HBV (0.87%), followed by HCV (0.34%), syphilis (0.17%), HIV (0.14%), and malaria (0.06%); nonetheless, a huge variation exists among different states. In India, all blood donations are mandatorily screened for human immunodeficiency virus 1/2 (HIV 1/2), hepatitis B virus (HBV), hepatitis C virus (HCV), and syphilis by serology as well as for malaria in accordance with the Drugs and Cosmetics Act, 1940. Nucleic acid amplification testing (NAT) added to standard screening can potentially enhance the sensitivity of screening. It can thus reduce the risk for TTIs, especially in a country of high prevalence such as India. There are several instances when serological assays fail to detect an infection while the NAT test can detect the presence of viral genome in the donated blood. Such a sample that is sero-nonreactive but NAT reactive is called a “NAT yield.”

The decision to initialize screening by NAT requires considerations of availability of infrastructure, skilled manpower, and the cost involved in procuring consumables and equipment. The challenges seem even more onerous when contemplating widespread implementation with an aim to benefit a large number of patients with limited resources at their disposal. This report outlines the initiative of the government of Odisha to furnish NAT screening in the government-run blood banks through the adoption of the public-private partnership (PPP) model.

Implementation of NAT through PPP Model

Recognizing the benefit that NAT tested blood brings to the patients, Odisha became the first state in India, to have implemented nucleic acid testing (NAT) at the state level. This project aimed to provide the people of Odisha access to safer blood by implementing sophisticated screening methods in government-run blood banks. The project was operationalized by the government of Odisha under the public-private partnership (PPP) with Roche Diagnostics India Pvt. Ltd. To provide equal access to NAT-tested blood for all patients, irrespective of their socioeconomic status, the government has subsidized 100% of the additional cost of NAT testing to the patients, thereby providing quality medical care to the people of Odisha.

The objective of this study was to evaluate the incremental yield of minipool nucleic acid testing compared with serology testing using a highly sensitive NAT, the cobas TaqScreen MPX test, version 2.0 (MPX2) for blood screening to validate the installation of NAT PCR system.

Materials and Methods

Adaptation of NAT Testing through PPP

Once it was decided by the Department of Health and Family Welfare of the Government of Odisha to adopt NAT screening for transfusion-transmitted infections besides serological screening tests, the government formed a technical resource group of experts from various functions to give recommendations on the implementation of NAT screening. The group recommended the implementation of automated NAT testing and the adoption of the PPP model due to considerations of human resource requirement, expertise building, investment, and convenience in running day-to-day operations. The project was implemented through a hub and spoke model to maximize access and laboratory efficiency and minimize expenditure. It has been executed in a phased manner.

In the currently ongoing phase 1, NAT PCR laboratories were established in four blood banks while testing was extended to two satellite blood banks. The private partner provided expertise for infrastructure development, setting up the laboratory in four blood banks, and training NAT laboratory associates. State Blood Transfusion Council (SBTC) was the nodal body that supervised and monitored the six sites through a Nodal Officer. Gradually, the blood banks became well versed with the SOP prepared by SBTC for NAT testing and reporting. The samples from the satellite blood banks were sent to the respective associated blood banks and were conveyed the NAT results within 24 hours of sample collection by the NAT laboratory associate. The blood components which were NAT reactive were released for the issue to patients who were NAT non-reactive. NAT testing was smoothly implemented through the PPP model in the six centers of the state. It was decided to expand the scope of the project to the entire state of Odisha if the pilot proved successful.

Study Design, Study Centers, Methodology, and Inclusion Criteria

This retrospective multi-centric study was conducted over a period of 2 years and 4 months from June 2016 to September 2018 across six government-run blood banks in Odisha that had access to NAT under the government project. The four testing centers were Capital Hospital (CAPITAL), Bhubaneswar; Sri-Rama Chandra Bhanja Medical College and Hospital (SCBMCH), Cuttack; Veer Surendra Sai Institute of Medical Sciences and Research (VIMSAR), Burla; and, Odisha Red Cross Blood Bank, Maharaja Krishna Chandra Gajapati Medical College Hospital (MIKGMCH), Berhampur. In addition, the two satellite blood banks, BMC Hospital, Bhubaneswar whose samples were processed at Capital Hospital, Bhubaneswar and Central Red Cross Blood Bank (CRC), Cuttack whose samples were processed at SCBMCH, Cuttack, were included. A total of 3,39,472 blood donations collected at the six study sites were included in the study. Overall, 2,11,016 (62.2%) were from voluntary donors, and 1,28,456 (37.8%) from replacement. The highest proportion of voluntary donors was in BMC (98.1%) and the lowest in CRC (51.5%).
All donations were tested by serology. A total of 3,27,241 sero-nonreactive donations were tested by NAT. As NAT screening was implemented over a period of 1-month at these six sites, not all sero-nonreactive donations collected in the month were tested by NAT, leading to the difference in the number of sero-nonreactive donations and those tested on NAT.

Serological screening of all blood donations collected during this timeframe was performed using the third-generation ELISA kits for HBsAg (by ERBA LISA PICO HBsAg), anti-HCV (by ERBA LISA PICO HCV), anti-HIV 1 + 2 (by ERBA LISA PICO HIV 1 + 2 TRANSASIA Bio-Medicare Pvt. Ltd.) provided by the Government of Odisha to all government blood banks on semi-automated ELISA platforms to maintain the uniformity of screening in all centers. The donations were also screened for syphilis (by Carbogen TULIP Diagnostic Pvt. Ltd.) and malaria (HRP-2, LDH MyTest By Bio-footprints Health care Pvt. Ltd.) by rapid tests. All assays were performed according to the manufacturers’ instructions. Along with the quality control of the reagents beforehand, an appropriate negative control was incorporated in all procedures. The donations reactive for any of the above were discarded per the blood bank SOP and the non-reactive donations were further subjected to NAT.

All donations were tested by serology. A total of 3,27,241 sero-nonreactive donations were tested by NAT. As NAT screening was implemented over a period of 1-month at these six sites, not all sero-nonreactive donations collected in the month were tested by NAT, leading to the difference in the number of sero-nonreactive donations and those tested on NAT.

NAT was performed by the Roche cobas TaqScreen MPX Test v2.0 on cobas s 201 System (Roche Molecular Systems, Branchburg, USA). Cobas TaqScreen MPX Test v2.0 is a qualitative multiplex test based on PCR and can detect and discriminate between HBV, HCV, HIV-1 groups M and O and HIV-2, simultaneously. Donor samples were pooled in minipools of six using the Hamilton Microlab STAR pipettor (Hamilton, Reno, NV). NAT was performed following the manufacturer’s instructions for the assay and automated platform. A reactive minipool was resolved by testing single units of the six members of the pool to identify the reactive donation and the viral cause of the reaction. The reactive donations were discarded per the Blood Bank SOP, and nonreactive units were released for transfusion in accordance with the planned screening algorithm for donated blood shown in Fig. 1. The 95% detection limits for MPX2 are shown in Table 1.

**Analytical Sensitivity: Limits of Detection**

The limits of detection (LOD) of the cobas TaqScreen MPX Test, v2.0 for HIV-1 Group M RNA, HIV-1 Group O RNA, HIV-2 RNA, HCV RNA, and HBV DNA were determined using the following standards: the WHO Second International Standard for HIV-1 RNA, Second International Standard (NIBSC code 97/650), the WHO International Standard for Hepatitis B virus DNA for Nucleic Acid Amplification Technology (NAT) assays (NIBSC code 97/746), the WHO Second International Standard for Hepatitis C Virus RNA for Genomic Amplification Technology Assays (NIBSC code 96/798), and the Roche Primary Standards for HIV-1 Group O and HIV-2. Additionally, the LOD of the cobas TaqScreen MPX Test, v2.0 for HIV-2 was determined using the HIV-2 RNA International Standard (NIBSC code 08/150). No international standard is currently available for HIV-1 Group O RNA. For the WHO and Roche standards, three independent dilution series of each viral standard were prepared with pooled human plasma collected in EDTA anticoagulant. Each dilution series was tested using three different lots of the cobas TaqScreen MPX Test, v2.0 kits with approximately 20 replicates per lot, for approximately 180 replicates per concentration. For the HIV-2 International Standard, 10 replicates per lot from three independent dilutions and three reagent lots were tested for 90 replicates per concentration. Finally, analysis of the combined data from all replicates tested for each virus was used to estimate the LOD.

**Table 1** Detection limits for NAT assays used in the study

| Target            | 95% LOD of cobas® TaqScreen MPX Test, v2.0 |
|-------------------|--------------------------------------------|
| HBV               | 6 IU/mL                                    |
| HCV               | 6.8 IU/mL                                  |
| HIV-1 Group M     | 50.3 IU/mL                                 |
| HIV-1 Group O     | 18.3 copies/mL                             |
| HIV-2             | 57.4 copies/mL                             |

Abbreviation: LOD, limit of detection.

The level at which 95% of test results would be expected to be reactive.
As per the Blood Bank Standard Operating Procedures, any donor reactive on a serological or NAT screening assay was informed and counseled about the results of the screening test and asked to follow up with the relevant specialty for confirmation and further management, if any. Donors identified as reactive on serology or NAT were not allowed to donate again. Other healthy donors who were previously seronegative through serology/NAT testing and came back for repeat donation again were not excluded from the study. They were further evaluated with both the screening tests, that is, ELISA followed by NAT testing.

**Statistical Analysis**

Our study was conducted as a descriptive study showing incremental reactivity with NAT over serology. As no comparison was intended, tests of significance were not applied. Any yield obtained with NAT over and above serology is considered important. All data were entered electronically in Microsoft Excel 2016. Descriptive statistics were used, and no statistical tests were performed. Data variables in the study have been presented as an absolute or relative frequency in the form of percentages.

**Results**

**Serological Testing**

The seroreactivity results of 3,39,472 blood donations from six study sites are given in Fig. 2. A total of 4,551 seroreactive donations were detected (1.34%). Overall, seroreactivity was the highest for HBV (1.07%), followed by HCV (0.10%), HIV (0.09%), malaria (0.05%), and syphilis (0.03%). The proportions of seroreactive donations detected out of total blood donations at the study sites from west to east were 3.08% at MKCGMCH, 1.31% at SCBMCH, and 1.3% at CAPITAL. The seroreactivity at other centers was less than 1%. The highest seroreactivity for HBV and HIV was found at MKCGMCH (2.75% and 0.15%, respectively), while the highest seroreactivity for HCV was found at SCBMCH (0.17%).

Of the total 4,551 seroreactive donations detected at all study sites, 80% were HBV-reactive, 8% HCV-reactive, 7% HIV-reactive, 4% malaria-reactive, and 2% syphilis-reactive. However, out of the total seroreactive donations detected at each study site, 74 to 89% were HBV-reactive, 4 to 14% were HCV-reactive, 5 to 10% were HIV-reactive, with lesser proportions of syphilis and malaria-reactive donations. The VIMSAR site was an exception to this pattern where the proportion of HBV was much lower (44%) and the proportion of malaria and syphilis was higher (22% and 11%, respectively) than other sites.

**Molecular Testing**

A total of 847 NAT-reactive donations were detected, and the overall NAT yield was 1:386 (0.26%). Although NAT testing was uniformly done in all centers on an automated platform, the NAT reactivity and NAT yield of sero-nonreactive donations varied in all study sites across Odisha, which is depicted in Table 2. Overall, MKCG MCH (1:158) followed by VIMSAR (1:272) showed a higher NAT yield compared with SCBMCH showing the lowest total NAT yield (1:1089). The HBV NAT yield and HCV NAT yield were the highest for MKCGMCH. However, the HIV NAT yield was the highest for VIMSAR. SCBMCH had the lowest yield for all three viruses: HBV (1:1208), HCV (1:27773), and HIV (1:18515).

NAT-reactivity was the highest for HBV (n = 695 amongst 847 donations, 82.5%), followed by HIV (n = 96 amongst 847 donations, 11.3%), and HCV (n = 59 amongst 847 donations, 6.9%).

**NAT-Reactivity Stratified by Voluntary/Replacement Status and Gender**

The information on NAT reactivity by voluntary/replacement status and gender is given in Table 3. The mean age of NAT reactive donors was 32.6 years.

**Discussion**

Our two and a half years of experience with the implementation of NAT screening on a statewide basis demonstrates the
success of the PPP model. The data presented here show the ability of NAT-PCR applied in a minipool format to identify infectious units over and above serology. This is one of the largest datasets from a large number of centers published so far, though smaller studies have been published.

NAT implementation in government-run blood banks is a state-of-art project of the Odisha government, operationalized under the PPP model with a private entity. The theoretical advantages of PPP such as improved efficiency with focused strategies and resources, and overcoming challenges of accessibility and affordability have been corroborated by our experience.12 The detection of a high number of serology-negative NAT reactive donations in our study revealed the significant benefits of NAT testing and validated the decision to implement NAT in the state. It paves the way for a statewide application of NAT. The government in addition, with a view to providing equal access to NAT-tested blood for all patients irrespective of their socioeconomic status, subsidizes 100% of the additional cost of NAT testing to the patients. This has not only served the purpose of providing quality medical care to people of Odisha but has also contributed toward the prevention of transmission of viral infections to recipients of transfusion and saving significant financial resources in the management of the infections.

The National AIDS Control Organization (NACO), under the Ministry of Health & Family Welfare, and National Blood Transfusion Council (NBTC) provided a report on the assessment of blood banks in Odisha from January 2015 to December 2015. HBV had the highest seropositivity (0.87%), followed by HCV (0.34%), and HIV (0.14%).13 Accordingly, in the present

### Table 2 NAT reactivity and NAT yield of sero-nonreactive donations at study sites across Odisha

| Site          | No. of donations tested by NAT | HBV (n) | HCV (n) | HIV (n) | Total NAT reactive donations (n) | HBV yield | HCV yield | HIV yield | Total NAT yield |
|---------------|--------------------------------|---------|---------|---------|---------------------------------|-----------|-----------|-----------|----------------|
| CAPITAL (N = 53,663) | 79                              | 10      | 12      | 101     | 1:679                           | 1:5,366   | 1:4,472   | 1:531     |
| BMC (N = 18,758)   | 36                              | 7       | 2       | 45      | 1:521                           | 1:2,680   | 1:9,379   | 1:417     |
| SCBMCH (N = 55,546) | 46                             | 2       | 3       | 51      | 1:1,208                         | 1:27,773  | 1:18,515  | 1:1,089   |
| CRC (N = 99,876)    | 108                             | 7       | 12      | 127     | 1:925                           | 1:14,268  | 1:8,323   | 1:786     |
| VIMSAR (N = 40,302) | 105                            | 7       | 36      | 148     | 1:384                           | 1:5,757   | 1:1,120   | 1:272     |
| MKCGMCH (N = 59,096) | 319                           | 25      | 31      | 375     | 1:185                           | 1:2,364   | 1:1,906   | 1:158     |
| Total (N = 327,241) | 695                            | 59      | 96      | 847     | 1:472                           | 1:5,642   | 1:3,409   | 1:386     |

### Table 3 NAT-reactivity stratification based on voluntary/replacement status and gender

| Site         | V (n) (%) | R (n) (%) | V + R (n) | V-NAT yields (n) (%) | R-NAT yields (n) (%) | Total NAT yields (V + R) | M-NAT yields (n) | F-NAT yields (n) |
|--------------|-----------|-----------|-----------|---------------------|---------------------|------------------------|----------------|----------------|
| CAPITAL      | 39,099 (70.8) | 16,098 (29.2) | 55,197   | 72 (71.3)           | 29 (28.7)           | 101                    | 94             | 2              |
| BMC          | 18,639 (98.1) | 359 (1.9)   | 18,998   | 45 (100.0)          | 0 (0)               | 45                     | 45             | 0              |
| SCBMCH       | 30,743 (54.4) | 25,731 (45.6) | 56,474   | 24 (51.1)           | 23 (48.9)           | 51                     | 42             | 4              |
| CRC          | 54,336 (51.5) | 51,133 (48.5) | 1,05,469 | 60 (47.2)           | 67 (52.8)           | 127                    | 121            | 6              |
| VIMSAR       | 30,658 (74.5) | 10,517 (25.5) | 41,175   | –                  | –                  | 148                    | 144            | 4              |
| MKCGMCH      | 37,541 (60.4) | 24,618 (39.6) | 62,159   | 191 (51.1)          | 183 (48.9)          | 375                    | 370            | 4              |
| Total        | 2,11,016 (62.2) | 1,28,456 (37.8) | 3,39,472 | 392 (56.5)          | 302 (43.5)          | 694                    | 816            | 20             |
In India on NAT yield of 1:2,000 to 1:3,000 but was similar to most of the previous studies. The combined NAT yield of the six sites of our study is among the highest published in India. The study had some limitations such as non-collection of data on some of the variables. Thus, in the present study over a period of 2.5 years, approximately 2,541 (847 NAT yields x 3) TTIs were prevented. In other words, one TTI was interdicted per 128 transfusions.

The proportion of voluntary donors in the study was 62.2%; however, a lower proportion (56.5%) of NAT reactivity was found in the voluntary donors. This brings forth the importance of continuing to encourage voluntary donations. At the same time, it also points toward the continued need for rigorous screening even in the voluntary donors.

In our study, NAT yield was the highest for HBV at 1:472, followed by HIV at 1:3,409, and HCV at 1:5,642. The highest yield for HBV is expected as the incidence and prevalence of HBV in India are much higher than those of HCV and HIV. HBV is the most common viral infection amongst HBV, HCV, and HIV in the general population of India and also the most common infection found in blood banks through serology and NAT. 2, 13–15, 17-20 Similar situation is observed in Odisha. Hence, the HBV seroreactivity and HBV NAT yield were both high in our study. It has been demonstrated earlier that cobas TaqScreen assays detects HBV infections less than 2.3 IU/mL in concentration. 17, 21 It is important in regions with a high prevalence of HBV, where the possibility of window period donations and occult infections with low viral loads is high, that an assay that is very sensitive for the detection and identification of HBV DNA be used.

Interestingly, in this study, the next common yield to HBV was HIV. In general, HIV is found to be the least common NAT yield in most studies from across India reflecting the much lower prevalence of HIV than HCV and HBV in the country. 20-22 The prevalence of HIV in the population aged 15 to 49 years in Odisha is found to be 0.13%. The high NAT yield in our study could possibly be due to the lower effectiveness of the HIV serology screening assay.

The highly sensitive MPX2 NAT assay used on cobas s 201 system offers additional advantages. It is a real-time PCR-based assay that requires low sample volumes for the detection of DNA/RNA. The multiplex and multi-dye technology utilized in this assay allows simultaneous detection and real-time target identification within a single test. The system is completely automated, requires no calibration, uses ready-to-use reagents, avoids cross-contamination by using the enzyme AmpErase, and works with minimal maintenance. The screening algorithm is simple and requires testing of only sero-nonreactive donations. Pooling reduces the number of tests performed and cost and improves specificity. The minipool test has a low limit of detection and has the capacity to detect HBV infections with viral load less than 6 IU/mL, which indicates the acceptable high sensitivity also.

The study had some limitations such as non-collection of viral load and follow-up data for seroconversion. In addition, being a retrospective study, data on some of the variables are missing from some centers. Nonetheless, this is a very large study of approximately 3.4 lac donations that showed the very high NAT yields that could be identified using a highly sensitive NAT assay.
Conclusion

The results of the present study revealed the incremental identification of potentially infectious donations by screening minipooled samples after being found nonreactive by serology assays. The advantages of using an automated molecular screening system were also amply clear. Minipool NAT-PCR could detect HBV, HCV, and HIV infections over and above serology testing. The high HBV yield observed in this study supported the use of a high sensitivity assay to detect HBV. Considering the high prevalence of viral infections, the number of transfusions, and the high proportion of component separation in the country, there is an acute unmet need for NAT testing to prevent TTIs. The PPP model applied in Odisha State can serve as a template for application across other states in India. PPP is a convenient step toward making NAT-testing a norm in the country. Our study not only presents the benefits of minipool NAT PCR testing but also presents a scalable model for the application of NAT throughout blood banks in India.

Authors’ Contributions
All the authors contributed to the concept, design, data collection, data analysis, interpretation of data, and critically reviewing the manuscript. All authors approved the final version of the manuscript.

Funding
None.

Conflicts of Interest
None declared. This manuscript has been read and approved by us, the requirements for authorship as stated earlier in this document have been met, and we believe that the manuscript represents original work.

Acknowledgments
We would like to thank Turacoz Healthcare Solutions, Gurugram India (www.turacoz.com) for the manuscript writing support.

References
1 National AIDS Control Organisation (NACO). A Report on Rapid Situation Assessment of Blood Transfusion Services in India. New Delhi: NACO; 2014
2 National AIDS Control Organisation (NACO), National Blood Transfusion Council (NBTC), Assessment of Blood Banks in India-2016. In: India MoHFW, ed. 2016:1–81:21–22
3 Chaurasia R, Zaman S, Das B, Chatterjee K. Screening donated blood for transfusion transmitted infections by serology along with NAT and response rate to notification of reactive results: an Indian experience. J Blood Transfus 2014;2014:412105
4 Shrivastava M, Mishra S. Nucleic acid amplification testing (NAT): an innovative diagnostic approach for enhancing blood safety. National Journal of Laboratory Medicine. 2017;6(02):IR01–IR06
5 Pandey P, Tiwari AK, Dara RC, Rawat GS, Negi A, Raina V. Confirmation and follow up of initial “NAT yields”: Prospective study from a tertiary healthcare center in India. Transfus Apher Sci 2016;54(02):242–247
6 Hans R, Marwaha N. Nucleic acid testing-benefits and constraints. Asian J Transfus Sci 2014;8(01):2–3
7 Guidelines On Estimation Of Residual Risk Of Hiv WHO. HBV or HCV infections via cellular blood components and plasma. Expert Committee On Biological Standardization Geneva, 2016;15;
8 Holmes H, Davis C, Heath A, Hewlett I, Lelie N. An international collaborative study to establish the 1st international standard for HIV-1 RNA for use in nucleic acid-based techniques. J Virol Methods 2001;92(2):141–150
9 Saldanha J, Gerlich W, Lelie N, Dawson P, Heeremann K, Heath AW. WHO Collaborative Study Group. An international collaborative study to establish a World Health Organization international standard for hepatitis B virus nucleic acid amplification techniques. Vox Sang 2001;80(01):63–71
10 Saldanha J, Heath A, Abraham C, Albrecht J, Gentili G, Gessner M, and Pisani G. WHO Collaborative Study to Establish a Replacement WHO International Standard for HCV RNA NAT Assays. WHO/B5/03.1958 Expert Committee on Biological Standardization, Geneva, Feb 17–21; 2003
11 HIV-2 RNA International Standard. (NIHSC code 08/150): Available at: http://www.nibsc.ac.uk/products/biological_reference_materials/product_catalogue/detail_page.aspx?catid =08/150
12 Thadani KB. Public private partnership in the health sector: boon or bane. Procedia Soc Behav Sci 2014;157:307–316
13 NACO. A Report on the “Assessment of Blood Banks in Odisha, India”. 2015;18;
14 Jain R, Aggarwal P, Gupta GN. Need for nucleic acid testing in countries with high prevalence of transfusion-transmitted infections. ISRN Hematol 2012;2012:718671
15 Chigurupati P, Murthy KS. Automated nucleic acid amplification testing in blood banks: an additional layer of blood safety. Asian J Transfus Sci 2015;9(01):9–11
16 Pathak S, Chandrashekhar M. Transfusion transmissible infections - seroprevalence among blood donors in a tertiary care hospital of Delhi. Asian J Transfus Sci 2013;7(02):116–118
17 Chigurupati P, Murthy KS. Role of nucleic acid testing in “double” screening of blood donors for a safe blood transfusion. Int J Microbiol Res 2016;8(10):794–796
18 National Viral Hepatitis Control Program Operational Guidelines. [updated 2018; cited October 2021]. Accessed Feb 7, 2022 from: https://www.inasl.org.in/national-viral-hepatitis-control-program.pdf
19 National AIDS Control Organization & ICMR-National Institute of Medical Statistics. HIV Estimations 2017: Technical Report. New Delhi: NACO, Ministry of Health and Family Welfare, Government of India, 2018
20 Chandra T, Rizvi SNF, Agarwal D. Nucleic acid testing in blood donors of northern India: a single centre experience. International Journal of Contemporary Medical Research 2016;3(06): 1818–1821
21 Chandra T, Agarwal D, Rizvi SN. Prevalence of HIV, HCV, HBV infection in blood donors detected by nucleic acid testing: an Indian experience. Eur J Pharm Med Res 2016;3(01):278–292
22 Ghosh K, Mishra K. Nucleic acid amplification testing in Indian blood banks: a review with perspectives. Indian J Pathol Microbiol 2017;60(03):313–318